Logo

Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India

Share this

Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India

Shots:

  • DCGI has granted the marketing authorization to Enzene’s Romiplostim biosimilar for the treatment of chronic ITP in adults
  • The company provides all the three dosage strengths of the product (125mcg- 250mcg- and 500mcg)
  • Romiplostim is an Fc-peptide fusion protein that increases platelet production through activation of the thrombopoietin receptor. The company’s first biosimilar Teriparatide has been launched in early 2021 for the treatment of osteoporosis

Ref: PRnewswire | Image: Stat News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions